Literature DB >> 16791278

Conserved extended haplotypes of the major histocompatibility complex: further characterization.

M T Dorak1, W Shao, H K G Machulla, E S Lobashevsky, J Tang, M H Park, R A Kaslow.   

Abstract

Since the complete sequencing of a human major histocompatibility complex (MHC) haplotype, interest in non-human leucocyte antigen (HLA) genes encoded in the MHC has been growing. Non-HLA genes, which outnumber the HLA genes, may contribute to or account for HLA and disease associations. Most information on non-HLA genes has been obtained in separate studies of individual loci. To comprehensively address polymorphisms of relevant non-HLA genes in 'conserved extended haplotypes' (CEH), we investigated 101 International Histocompatibility Workshop reference cell lines and nine additional anonymous samples representing all 37 unambiguously characterized CEHs at MICA, NFKBIL1, LTA, NCR3, AIF1, HSPA1A, HSPA1B, BF, NOTCH4 and a single nucleotide polymorphism (SNP) at HLA-DQA1 as well as MICA, NOTCH4, HSPA1B and all five tumour necrosis factor short tandem repeat (STR) polymorphisms. This work (1) provides an extensive catalogue of MHC polymorphisms in all CEHs, (2) unravels interrelationships between HLA and non-HLA haplotypical lineages, (3) resolves reported typing ambiguities and (4) describes haplospecific markers for a number of CEHs. Analysis also identified a DQA1 SNP and segments containing MHC class III polymorphisms that corresponded with class II (DRB3 and DRB4) lineages. These results portray the MHC where lineages containing non-HLA and HLA variants in linkage disequilibrium may operate in concert and can guide more thorough design and interpretation of HLA-disease relationships.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791278     DOI: 10.1038/sj.gene.6364315

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  25 in total

Review 1.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

2.  Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing.

Authors:  Paul J Norman; Jill A Hollenbach; Neda Nemat-Gorgani; Wesley M Marin; Steven J Norberg; Elham Ashouri; Jyothi Jayaraman; Emily E Wroblewski; John Trowsdale; Raja Rajalingam; Jorge R Oksenberg; Jacques Chiaroni; Lisbeth A Guethlein; James A Traherne; Mostafa Ronaghi; Peter Parham
Journal:  Am J Hum Genet       Date:  2016-08-04       Impact factor: 11.025

3.  Next-generation HLA typing of 382 International Histocompatibility Working Group reference B-lymphoblastoid cell lines: Report from the 17th International HLA and Immunogenetics Workshop.

Authors:  Lisa E Creary; Sandra G Guerra; Winnie Chong; Colin J Brown; Thomas R Turner; James Robinson; Will P Bultitude; Neema P Mayor; Steven G E Marsh; Katsuyuki Saito; Kevin Lam; Jamie L Duke; Timothy L Mosbruger; Deborah Ferriola; Dimitrios Monos; Amanda Willis; Medhat Askar; Gottfried Fischer; Chee Loong Saw; Jiannis Ragoussis; Martin Petrek; Carles Serra-Pagés; Manel Juan; Catherine Stavropoulos-Giokas; Amalia Dinou; Reem Ameen; Salem Al Shemmari; Eric Spierings; Ketevan Gendzekhadze; Gerald P Morris; Qiuheng Zhang; Zahra Kashi; Susan Hsu; Sridevi Gangavarapu; Kalyan C Mallempati; Fumiko Yamamoto; Kazutoyo Osoegawa; Tamara Vayntrub; Chia-Jung Chang; John A Hansen; Marcelo A Fernández-Viňa
Journal:  Hum Immunol       Date:  2019-03-04       Impact factor: 2.850

4.  Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations.

Authors:  Howard W Wiener; Sadeep Shrestha; Hailin Lu; Etienne Karita; William Kilembe; Susan Allen; Eric Hunter; Paul A Goepfert; Jianming Tang
Journal:  Hum Immunol       Date:  2017-12-28       Impact factor: 2.850

5.  Very long haplotype tracts characterized at high resolution from HLA homozygous cell lines.

Authors:  Paul J Norman; Steve J Norberg; Neda Nemat-Gorgani; Thomas Royce; Jill A Hollenbach; Melissa Shults Won; Lisbeth A Guethlein; Kevin L Gunderson; Mostafa Ronaghi; Peter Parham
Journal:  Immunogenetics       Date:  2015-07-22       Impact factor: 2.846

6.  Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer.

Authors:  Margaret M Madeleine; Lisa G Johnson; Mari Malkki; Alexa J Resler; Effie W Petersdorf; Barbara McKnight; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2011-04-27       Impact factor: 4.872

7.  HLA complex-linked heat shock protein genes and childhood acute lymphoblastic leukemia susceptibility.

Authors:  Esma Ucisik-Akkaya; Charronne F Davis; Clara Gorodezky; Carmen Alaez; M Tevfik Dorak
Journal:  Cell Stress Chaperones       Date:  2009-12-09       Impact factor: 3.667

8.  Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.

Authors:  Yufeng Li; Rong Ni; Wei Song; Wenshuo Shao; Sadeep Shrestha; Sushma Ahmad; Coleen K Cunningham; Patricia M Flynn; Bill G Kapogiannis; Craig M Wilson; Jianming Tang
Journal:  Hum Genet       Date:  2009-07-14       Impact factor: 4.132

9.  Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations.

Authors:  Lora Boteva; David L Morris; Josefina Cortés-Hernández; Javier Martin; Timothy J Vyse; Michelle M A Fernando
Journal:  Am J Hum Genet       Date:  2012-03-01       Impact factor: 11.025

10.  HLA-class I markers and multiple sclerosis susceptibility in the Italian population.

Authors:  L Bergamaschi; M A Leone; M E Fasano; F R Guerini; D Ferrante; E Bolognesi; N Barizzone; L Corrado; P Naldi; C Agliardi; E Dametto; M Salvetti; A Visconti; D Galimberti; E Scarpini; M Vercellino; R Bergamaschi; F Monaco; D Caputo; P Momigliano-Richiardi; S D'Alfonso
Journal:  Genes Immun       Date:  2009-11-12       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.